These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1053 related articles for article (PubMed ID: 27240460)

  • 1. Oncolytic Immunotherapy for Treatment of Cancer.
    Tsun A; Miao XN; Wang CM; Yu DC
    Adv Exp Med Biol; 2016; 909():241-83. PubMed ID: 27240460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrating oncolytic viruses in combination cancer immunotherapy.
    Bommareddy PK; Shettigar M; Kaufman HL
    Nat Rev Immunol; 2018 Aug; 18(8):498-513. PubMed ID: 29743717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Critical Interactions between Immunogenic Cancer Cell Death, Oncolytic Viruses, and the Immune System Define the Rational Design of Combination Immunotherapies.
    van Vloten JP; Workenhe ST; Wootton SK; Mossman KL; Bridle BW
    J Immunol; 2018 Jan; 200(2):450-458. PubMed ID: 29311387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of oncolytic virus immunotherapies to subvert cancer immune evasion.
    Workenhe ST; Verschoor ML; Mossman KL
    Future Oncol; 2015; 11(4):675-89. PubMed ID: 25686121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.
    Rojas JJ; Sampath P; Hou W; Thorne SH
    Clin Cancer Res; 2015 Dec; 21(24):5543-51. PubMed ID: 26187615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncolytic Immunotherapy.
    Hennessy ML; Bommareddy PK; Boland G; Kaufman HL
    Surg Oncol Clin N Am; 2019 Jul; 28(3):419-430. PubMed ID: 31079797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors.
    Rajani KR; Vile RG
    Viruses; 2015 Nov; 7(11):5889-901. PubMed ID: 26580645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of oncolytic virotherapy: from genetic modification to combination therapy.
    Lan Q; Xia S; Wang Q; Xu W; Huang H; Jiang S; Lu L
    Front Med; 2020 Apr; 14(2):160-184. PubMed ID: 32146606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving antitumor efficacy via combinatorial regimens of oncolytic virotherapy.
    Zhang B; Cheng P
    Mol Cancer; 2020 Nov; 19(1):158. PubMed ID: 33172438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncolytic and immunologic cancer therapy with GM-CSF-armed vaccinia virus of Tian Tan strain Guang9.
    Deng L; Fan J; Guo M; Huang B
    Cancer Lett; 2016 Mar; 372(2):251-7. PubMed ID: 26803055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virus specific tolerance enhanced efficacy of cancer immuno-virotherapy.
    Sobhanimonfared F; Bamdad T; Sadigh ZA; Choobin H
    Microb Pathog; 2020 Mar; 140():103957. PubMed ID: 31891795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunomodulation in Oncolytic Measles Virotherapy.
    Dietz L; Engeland CE
    Methods Mol Biol; 2020; 2058():111-126. PubMed ID: 31486034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The viral approach to breast cancer immunotherapy.
    Arab A; Behravan N; Razazn A; Barati N; Mosaffa F; Nicastro J; Slavcev R; Behravan J
    J Cell Physiol; 2019 Feb; 234(2):1257-1267. PubMed ID: 30146692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virotherapy: From single agents to combinatorial treatments.
    Malfitano AM; Di Somma S; Iannuzzi CA; Pentimalli F; Portella G
    Biochem Pharmacol; 2020 Jul; 177():113986. PubMed ID: 32330494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncolytic HSV as a vector in cancer immunotherapy.
    Li H; Zhang X
    Methods Mol Biol; 2010; 651():279-90. PubMed ID: 20686972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Modulation by Telomerase-Specific Oncolytic Adenovirus Synergistically Enhances Antitumor Efficacy with Anti-PD1 Antibody.
    Kanaya N; Kuroda S; Kakiuchi Y; Kumon K; Tsumura T; Hashimoto M; Morihiro T; Kubota T; Aoyama K; Kikuchi S; Nishizaki M; Kagawa S; Tazawa H; Mizuguchi H; Urata Y; Fujiwara T
    Mol Ther; 2020 Mar; 28(3):794-804. PubMed ID: 31991110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncolytic viruses and immunity.
    Chaurasiya S; Chen NG; Fong Y
    Curr Opin Immunol; 2018 Apr; 51():83-90. PubMed ID: 29550660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current strategies to circumvent the antiviral immunity to optimize cancer virotherapy.
    Shin DH; Nguyen T; Ozpolat B; Lang F; Alonso M; Gomez-Manzano C; Fueyo J
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy Gone Viral: Bortezomib and oHSV Enhance Antitumor NK-Cell Activity.
    Suryadevara CM; Riccione KA; Sampson JH
    Clin Cancer Res; 2016 Nov; 22(21):5164-5166. PubMed ID: 27521450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncolytic virus immunotherapy: future prospects for oncology.
    Raja J; Ludwig JM; Gettinger SN; Schalper KA; Kim HS
    J Immunother Cancer; 2018 Dec; 6(1):140. PubMed ID: 30514385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.